(84 days)
None
No
The description details standard signal processing and algorithmic calculations based on physical measurements (Laser Doppler flowmetry and solid-state pressure sensing). There is no mention of AI, ML, or related concepts like training/test sets, image processing, or complex pattern recognition beyond basic signal conversion and derived variable calculation.
No.
The device is solely for monitoring cerebral blood flow and intracranial pressure, not for treating conditions.
Yes
The device is intended to monitor cerebral blood flow and intracranial pressure in patients at risk of cerebral ischemia, providing real-time measurements and derived variables like cerebral perfusion pressure and cerebrovascular resistance. These measurements and derived values are used to assess a patient's physiological state and potential medical conditions, which is characteristic of a diagnostic device.
No
The device description clearly outlines hardware components including a parenchymal probe with sensors (Laser Doppler and solid state), a monitor for display and storage, a cranial access port, and a convenience procedure kit. While software is involved in processing and displaying data, it is part of a larger hardware system.
Based on the provided information, the NeuroSensor™ System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens (like blood, urine, or tissue) taken from the human body to provide information about a person's health. This testing is done outside of the body (in vitro).
- NeuroSensor™ System Function: The NeuroSensor™ System directly monitors physiological parameters (cerebral blood flow and intracranial pressure) within the patient's brain (in vivo). It uses a probe inserted into the cerebral tissue.
Therefore, because the NeuroSensor™ System operates directly within the patient's body to measure physiological parameters, it falls under the category of an in vivo diagnostic or monitoring device, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The NeuroSensor™ system has been designed for use by a qualified neurosurgeon in monitoring cerebral blood flow in patients at risk of cerebral ischemia, and for the direct monitoring of intracranial pressure in both sub-dural and intraparenchymal applications.
Product codes
GWM, DPT, DPW
Device Description
The NeuroSensor™ system consists of a single-use combined 2mm diameter parenchymal probe for the real-time measurement of cerebral blood flow (CBF) and intracranial pressure (ICP) and a monitor for the display and storage of these measured variables and the computation and display of derived variables.
CBF is measured using Laser Doppler flowmetry and provides real-time measurements of local blood flow in the brain. In the NeuroSensor™ system, low power laser light at 780nm is transmitted down a central fiber to the tip of the probe and illuminates the cerebral tissue. The laser light is scattered by the moving red blood cells and is collected by an array of collecting fibers at the tip of the probe. The reflected light is measured and the resulting signal processed to produce a measure of the perfusion or flux of blood in the local tissue sample volume. The flow measurement is converted into absolute units of ml/min/100g using an algorithm determined by a comparison between measurements made using the combined Laser Doppler probe and the reference method of Quantitative Autoradiography.
ICP is monitored directly by a solid state sensor mounted on the side of the NeuroSensor™ probe close to its tip. The sensor is precalibrated in the factory with probe identification and calibration values stored within each probe and there is no requirement for the user to calibrate the probe before use.
The NeuroSensor™ monitor uses a color LCD display to show the two measured variables CBF and ICP continuously in real time, both in digital form and as a realtime trace. The monitor can accept measured arterial pressure from an external patient monitor, and can use this data and the measured CBF and ICP to derive cerebral perfusion pressure (CPP) and cerebrovascular resistance (CVR). Data is stored by the monitor and can be displayed as a trend graph over a period of 15 minutes, or 1,2,8 or 24 hours.
Completing the system is a single-use cranial access port featuring a titanium alloy bolt, and a convenience procedure kit for cranial access.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Brain (intraparenchymal, sub-dural applications)
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Qualified neurosurgeon
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
In vitro testing shows that the device meets similar performance specifications as those for the predicate devices.
Key Metrics
Not Found
Predicate Device(s)
K914479, K896515, K961368, K974088
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 882.1620 Intracranial pressure monitoring device.
(a)
Identification. An intracranial pressure monitoring device is a device used for short-term monitoring and recording of intracranial pressures and pressure trends. The device includes the transducer, monitor, and interconnecting hardware.(b)
Classification. Class II (performance standards).
0
FEB 2 0 2002
510(k) Summary
November 26th 2001
013930 1/3
Submitter 1
Novus Monitoring Ltd Greenways Abbotts Ann, Andover
Hampshire, SP11 7BH United Kingdom
| Contact Person: | Prof. Peter F Gibson |
|---|---|
| Telephone: | +44 1264 711080 |
| Facsimile: | +44 1264 711083 |
2 Name of Device
| Proprietary Name: | NeuroSensor TM system, comprising:
a) NeuroSensorTM monitor
b) NeuroSensorTM parenchymal probe
c) NeuroSensorTM cranial access port
d) NeuroSensorTM cranial access procedure kit |
|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Common Name: | a) Cerebral Blood Flow and Intracranial Pressure
monitor
b) Parenchymal probe for cerebral blood flow and
intracranial pressure measurement
c) Intracranial bolt
d) Convenience procedure kit for cranial access |
| Device Classification: | Intracranial pressure monitoring devices have been placed in
Class II as per 21 CFR Regulation Number 882.1620 and
assigned the Product Code GWM.
Extravascular blood flow probes and blood flowmeters have
been placed in Class II as per 21 CFR Regulation Number
870.2120 (Product Code DPT) and 21 CFR 870.2100 |
Predicate Devices 3
The components of the NeuroSensor™ system are substantially equivalent to the following legally marketed devices:
(Product Code DPW), respectively.
| K914479 | Codman ICP monitoring system and Microsensor™ ICP transducer |
|---|---|
| K896515 | Vasamedics Model BPM2 Laser Doppler Perfusion Monitor |
1
Vasamedics Trimflo™ parenchymal blood flow monitoring K961368 kit
Codman Intracranial Bolt K974088
This statement is based on the subject device's similarity to the predicate devices in intended use, materials, design and principles of operation.
Device Description 4
The NeuroSensor™ system consists of a single-use combined 2mm diameter parenchymal probe for the real-time measurement of cerebral blood flow (CBF) and intracranial pressure (ICP) and a monitor for the display and storage of these measured variables and the computation and display of derived variables.
CBF is measured using Laser Doppler flowmetry and provides real-time measurements of local blood flow in the brain. In the NeuroSensor™ system, low power laser light at 780nm is transmitted down a central fiber to the tip of the probe and illuminates the cerebral tissue. The laser light is scattered by the moving red blood cells and is collected by an array of collecting fibers at the tip of the probe. The reflected light is measured and the resulting signal processed to produce a measure of the perfusion or flux of blood in the local tissue sample volume. The flow measurement is converted into absolute units of ml/min/100g using an algorithm determined by a comparison between measurements made using the combined Laser Doppler probe and the reference method of Quantitative Autoradiography.
ICP is monitored directly by a solid state sensor mounted on the side of the NeuroSensor™ probe close to its tip. The sensor is precalibrated in the factory with probe identification and calibration values stored within each probe and there is no requirement for the user to calibrate the probe before use.
The NeuroSensor™ monitor uses a color LCD display to show the two measured variables CBF and ICP continuously in real time, both in digital form and as a realtime trace. The monitor can accept measured arterial pressure from an external patient monitor, and can use this data and the measured CBF and ICP to derive cerebral perfusion pressure (CPP) and cerebrovascular resistance (CVR). Data is stored by the monitor and can be displayed as a trend graph over a period of 15 minutes, or 1,2,8 or 24 hours.
Completing the system is a single-use cranial access port featuring a titanium alloy bolt, and a convenience procedure kit for cranial access.
2
5 Intended Use
The NeuroSensor™ system has been designed for use by a qualified neurosurgeon in monitoring cerebral blood flow in patients at risk of cerebral ischemia, and for the direct monitoring of intracranial pressure in both sub-dural and intraparenchymal applications.
Summary of Substantial Equivalence 6
The NeuroSensor™ system is similar in design, construction, materials, intended use and performance characteristics to the predicate devices. It differs in combining the measurement of CBF and ICP into a single combined probe. In vitro testing shows that the device meets similar performance specifications as those for the predicate devices. No new issues of safety or effectiveness are introduced by using this device.
3
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three stripes forming its body and wings. The eagle is enclosed in a circle with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Mr. Peter F. Gibson Managing Director Novus Monitoring Ltd. Greenways Abbotts Ann, Andover Hampshire, SP11 7BH United Kingdom
FEB 2 0 2002
Re: K013930
Trade/Device Name: NeuroSensor™ System Regulation Number: 870.2120, 882.1620 Regulation Name: Extravascular blood flow probe Intracranial pressure monitoring device
Regulatory Class: II Product Code: DPW, GWM Dated: November 26, 2001 Received: November 28, 2001
Dear Mr. Gibson:
We have reviewed your Section 510(k) premarket notification of intent to market the device wo neve reviewed your be devere is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate for use stated in the entrebate) it the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The r ou mayy affects provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean r hat FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must or mr) i with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
4
Page 2 - Mr. Peter F. Gibson
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours,
Miriam C. Provost
for Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Indications for Use Statement
Ver/ 3 - 4/24/96
Novus Monitoring Ltd
510(k) Number (if known): Kol 393 3
Device Name:
Applicant:
NeuroSensor™ System
Indications For Use:
The NeuroSensor™ System is intended for use by a qualified neurosurgeon in monitoring cerebral blood flow in patients at risk of cerebral ischemia, and for the direct monitoring of intracranial pressure in both sub-dural and intraparenchymal applications.
Miriam C. Prorost
(Division Sign-Off) Division of General, Restorative and Neurological Devices
K013930 510(k) Number _
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTH
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Per 21 CFR 801.109)
(Optional Format 1-2-96)